Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Boostrix™10 Years After Previous Booster Vaccination

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they can and will comply with the requirements of the protocol.~* Male or female subjects who have received Boostrix™, Boostrix™-US formulation or the investigational vaccine formulation in the study 263855/029.~* Written informed consent obtained from the subject. Additional criteria to be checked before the booster vaccination.~* Healthy subjects as established by medical history and clinical examination.~* Female subjects of non-childbearing potential may receive the booster vaccine.~* Female subjects of childbearing potential may receive the booster vaccine, if the subject:~  * practices/has practiced adequate contraception for 30 days prior to vaccination, and~ * has a negative pregnancy test on the day of vaccination, and~ * agrees to continue adequate contraception during the entire booster epoch.~Exclusion Criteria:~Exclusion criteria to be checked at study entry:~* Previous booster vaccination against diphtheria, tetanus, or pertussis since the dose received in the study 263855/029.~* History of diphtheria, tetanus, or laboratory confirmed pertussis disease.~* Any confirmed or suspected immunosuppressive or immunodeficiency condition, based on medical history and physical examination.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.~* Occurrence of transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus.~* Occurrence of any of the following adverse event after a previous administration of a DTP vaccine :~  * hypersensitivity reaction to any component of the vaccine,~ * encephalopathy of unknown aetiology occurring within seven days following previous vaccination with pertussis-containing vaccine,~ * fever \>= 40 °C (axillary temperature) within 48 hours of vaccination not due to another identifiable cause,~ * collapse or shock-like state within 48 hours of vaccination,~ * convulsions with or without fever, occurring within three days of vaccination.~* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.~Additional exclusion criteria to be checked for subjects before the booster vaccination administration:~* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the booster dose of study vaccine, or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose.~* Administration of a vaccine not foreseen by the study protocol within 30 days prior to booster vaccination, or planned administration during the active study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Administration of immunoglobulins and/or any blood products within the three months preceding the booster dose or planned administration during the study period.~* Acute disease and/or fever at the time of enrolment.~  * Fever is defined as temperature ≥ 37.5°C on oral, axillary or tympanic setting.~ * Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.~* Pregnant or lactating female.~* Female planning to become pregnant or planning to discontinue contraceptive precautions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 28 Years
- Healthy Volunteers: t

Study Arms:
- Boostrix-REF Group (Type: EXPERIMENTAL): Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, reference formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, reference formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
- Boostrix-US Group (Type: EXPERIMENTAL): Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, United States(US)-marketed formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, US-marketed formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.
- Boostrix-INV Group (Type: EXPERIMENTAL): Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, investigational formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, reference formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).